# Effect of neoadjuvant chemotherapy on CD14 + CD16 + monocytes and soluble CD163 in Egyptian breast cancer patients

## TL;DR

This study examines how neoadjuvant chemotherapy affects immune cells and proteins in Egyptian breast cancer patients.

## Contribution

The study identifies CD14+CD16+ monocytes and soluble CD163 as potential predictors of chemotherapy response in breast cancer.

## Key findings

- Neoadjuvant chemotherapy significantly reduced CD14+CD16+ monocytes and soluble CD163 levels.
- Both CD14+CD16+ monocytes and soluble CD163 were linked to partial clinical response in patients.
- These markers may help predict treatment outcomes in breast cancer patients.

## Abstract

Neoadjuvant chemotherapy (NACT) influences the anticancer response by favourably altering the immune microenvironment. However, the effects of NACT on peripheral monocytes and their prognostic contribution to the NACT response have not yet been clarified. We aimed to evaluate the potential therapeutic responses and possible predictive value of double-positive (CD14 + CD16 +) monocytes and soluble CD163 (sCD163) in Egyptian breast cancer patients. Blood samples were obtained before and after neoadjuvant therapy from 30 patients with invasive breast cancer, and the expression of CD14 and CD16 was assessed via flow cytometry. The patients’ sCD163 levels were also determined in both the serum and culture supernatant using enzyme-linked immunosorbent assay (ELISA). The results revealed that NACT was associated with a significant decrease in double-positive monocytes and sCD163 levels. In addition, both double-positive monocytes and serum sCD163 were significantly associated with a partial clinical response. Double-positive monocytes and serum sCD163 levels may be related to therapeutic response, suggesting their possible predictive value in breast cancer patients receiving NACT.